Proteins

Screening Libraries

Bradykinin (1-7)

Cat. No.: HY-P1484 CAS No.: 23815-87-4 Molecular Formula: $C_{35}H_{52}N_{10}O_{9}$ Molecular Weight: 756.85

Sequence: Arg-Pro-Pro-Gly-Phe-Ser-Pro

Sequence Shortening: **RPPGFSP**

Target: **Bradykinin Receptor** GPCR/G Protein Pathway:

Storage: Sealed storage, away from moisture

> Powder -80°C 2 years

-20°C 1 year

$ H_2N$		NH N		
\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	9 (o HO	:0
N N	₩.\	₩ O	OH OH	

NHa

Product Data Sheet

SOLVENT & SOLUBILITY

In Vitro

H₂O: 100 mg/mL (132.13 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	
	1 mM	1.3213 mL	6.6063 mL	13.2127 mL	
	5 mM	0.2643 mL	1.3213 mL	2.6425 mL	
	10 mM	0.1321 mL	0.6606 mL	1.3213 mL	

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS

Solubility: 100 mg/mL (132.13 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

Bradykinin (1-7) is an amino-truncated Bradykinin peptide. Bradykinin (1-7) is a metabolite of Bradykinin, cleaved by endopeptidase.

In Vitro

The Bradykinin peptide system is a tissue-based system with potent cardiovascular and renal effects. To investigate the regulation of this system, a highly sensitive amino terminal-directed radioimmunoassay that, with high performance liquid chromatography, enables the measurement of Bradykinin-(1-7), Bradykinin-(1-8), and Bradykinin-(1-9), is developed. Together with a carboxy terminal-directed radioimmunoassay, Bradykinin peptides in rat kidney and blood are characterized. The predominant Bradykinin peptides in kidney are Bradykinin-(1-9) (~100 fmol/g wet weight of tissue) and Bradykinin-(1-7) (~70 fmol/g), with low levels of Bradykinin-(1-8) (~8 fmol/g) and Bradykinin-(4-9) (~12 fmol/g) detectable; Bradykinin-(2-9) and Bradykinin-(3-9) are below the limits of detection. In blood, the levels of Bradykinin-(1-9) are very low

^{*} In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

(~2 fmol/ml), and other Bradykinin peptides are below the limits ofdetection. Administration of the angiotensin converting enzyme (ACE) inhibitor Perindopril is associated with an approximate twofold increase in renal levels of Bradykinin-(1-8) and Bradykinin-(1-9) and a decrease in the Bradykinin-(1-7)/Bradykinin-(1-9) ratio. The amino terminal-directed radioimmunoassay is also applied to heart, aorta, brown adipose tissue, adrenal, lung, and brain. For these tissues, Bradykinin-(1-7) and Bradykinin-(1-9) are of similar abundance (16-340 fmol/g), with lower levels of Bradykinin-(1-8)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

				\mathbf{C}	

[1]. Campbell DJ, et al. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension. 1993 Feb;21(2):155-65.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 2 of 2 www.MedChemExpress.com